within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10X_OtherDrugsUsedInDiabetes.A10XX01_Teplizumab;

model Teplizumab
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 7.63888888888889e-08,
    adminDuration = 600,
    adminMass = 826 / 1000000,
    adminCount = 1,
    Vd = 0.007,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0036,
    k12 = 1.0555555555555557e-07,
    k21 = 1.0555555555555557e-07);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Teplizumab</td></tr><tr><td>ATC code:</td><td>A10XX01</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>826</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>7</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.275</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Teplizumab is a humanized anti-CD3 monoclonal antibody that modulates T lymphocyte function by binding to the CD3 epsilon chain. It has been developed to delay the onset of type 1 diabetes (T1D) in at-risk individuals with evidence of beta cell autoimmunity but not yet overt diabetes. Teplizumab received FDA approval in 2022 for delaying clinical type 1 diabetes in at-risk pediatric and adult patients.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adults and subjects with type 1 diabetes based on publicly available data and FDA label, as no detailed publication with full popPK model available.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A10XX01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Teplizumab;
